This protocol applies to patients with HIV infection who have clinical evidence of coccidioidomycosis and a peripheral blood CD4+ T-lymphocyte count below 250 cells/µL — a combination that defines a distinct high-risk subgroup and drives a specific management approach.
Antifungal therapy is indicated in this setting. Its continuation is directly linked to the patient's CD4+ T-lymphocyte count — the complete regimen, specific agent selection, and monitoring criteria are contained in the full structured protocol.
DOI: 10.1093/cid/ciw360
Antifungal therapy is recommended for all patients with HIV infection with clinical evidence of coccidioidomycosis and a peripheral blood CD4+ T-lymphocyte count <250 cells/µL (strong, moderate).
Antifungal therapy should be continued as long as the peripheral CD4+ T-lymphocyte count remains <250 cells/µL (strong, low).
View source ↗